Luca Vivona

Specializzando

Struttura:

E-mail:

Pubblicazioni

Titolo	Pubblicato in	Anno
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis	BMC CANCER	2024
Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis	BMC CANCER	2024
The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management	FRONTIERS IN ONCOLOGY	2023